SpectraWave Names Dr. Jonathan Hill as Chief Medical Officer

October 13, 2025—SpectraWave, Inc., a medical imaging company focused on coronary artery disease (CAD), announced the appointment of Jonathan Hill, MD, as Chief Medical Officer.

Dr. Hill, who is an interventional cardiologist from Royal Brompton Hospital in London, United Kingdom, has an extensive expertise in CAD, complex percutaneous coronary interventions, intravascular imaging, physiology, cardiovascular innovation, and clinical study design and implementation, stated SpectraWave.

“I am honored to join SpectraWave at such a pivotal time,” commented Dr. Hill in the company’s press release. “The company’s approach to combining intravascular imaging and physiology in a comprehensive and easy-to-use form factor is going to transform decision-making in the cath lab. I look forward to collaborating with the incredible team and the global clinical community as we expand the impact of HyperVue and introduce new technologies and clinical indications beyond intravascular imaging.”

The company advised that it recently completed enrollment of a 175-patient United States clinical workflow study of HyperVue intravascular imaging system with the next-generation DeepOCT images and near-infrared spectroscopy. Results are scheduled to be presented at TCT 2025, the Transcatheter Cardiovascular Therapeutics meeting.

In addition, SpectraWave noted that it has initiated a multisite United States study evaluating its upcoming single-angiogram, wire-free fractional flow reserve technology, currently under review by the FDA.